204 related articles for article (PubMed ID: 19585288)
1. The cost of relapse in schizophrenia and schizoaffective disorder.
Fitzgerald P; de Castella A; Arya D; Simons WR; Eggleston A; Meere S; Kulkarni J
Australas Psychiatry; 2009 Aug; 17(4):265-72. PubMed ID: 19585288
[TBL] [Abstract][Full Text] [Related]
2. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
3. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
4. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index.
Laursen TM; Agerbo E; Pedersen CB
J Clin Psychiatry; 2009 Oct; 70(10):1432-8. PubMed ID: 19538905
[TBL] [Abstract][Full Text] [Related]
5. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study.
Hong J; Windmeijer F; Novick D; Haro JM; Brown J
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):835-41. PubMed ID: 19351551
[TBL] [Abstract][Full Text] [Related]
6. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
7. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity.
Nakonezny PA; Byerly MJ; Rush AJ
Psychiatry Res; 2008 Jan; 157(1-3):259-63. PubMed ID: 17935793
[TBL] [Abstract][Full Text] [Related]
8. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
Taylor D; Hayhurst K; Kerwin R
Int Clin Psychopharmacol; 2007 May; 22(3):133-6. PubMed ID: 17414738
[TBL] [Abstract][Full Text] [Related]
9. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.
Eaddy M; Grogg A; Locklear J
Clin Ther; 2005 Feb; 27(2):263-72. PubMed ID: 15811492
[TBL] [Abstract][Full Text] [Related]
10. Remission and relapse after the first hospital admission in psychotic depression: a 4-year naturalistic follow-up.
Naz B; Craig TJ; Bromet EJ; Finch SJ; Fochtmann LJ; Carlson GA
Psychol Med; 2007 Aug; 37(8):1173-81. PubMed ID: 17335639
[TBL] [Abstract][Full Text] [Related]
11. Family intervention in schizophrenia--impact on family burden and attitude.
Berglund N; Vahlne JO; Edman A
Soc Psychiatry Psychiatr Epidemiol; 2003 Mar; 38(3):116-21. PubMed ID: 12616308
[TBL] [Abstract][Full Text] [Related]
12. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
Lafeuille MH; Gravel J; Lefebvre P; Fastenau J; Muser E; Doshi D; Duh MS
J Med Econ; 2013 Nov; 16(11):1290-9. PubMed ID: 24006903
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
[TBL] [Abstract][Full Text] [Related]
14. Gender related differences in clinical characteristics and hospital based resource utilization among older adults with schizophrenia.
Sajatovic M; Sultana D; Bingham CR; Buckley P; Donenwirth K
Int J Geriatr Psychiatry; 2002 Jun; 17(6):542-8. PubMed ID: 12112178
[TBL] [Abstract][Full Text] [Related]
15. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics.
Fitzgerald PB; Montgomery W; de Castella AR; Filia KM; Filia SL; Christova L; Jackson D; Kulkarni J
Aust N Z J Psychiatry; 2007 Oct; 41(10):819-29. PubMed ID: 17828655
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder.
Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R
J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686
[TBL] [Abstract][Full Text] [Related]
17. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
[TBL] [Abstract][Full Text] [Related]
18. Remission in schizophrenia: analysis in a naturalistic setting.
Eberhard J; Levander S; Lindström E
Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
[TBL] [Abstract][Full Text] [Related]
19. Cost of care for new versus recurrent acute coronary syndrome patients.
Shetty S; Halpern R; McCollam PL
J Med Econ; 2008; 11(1):81-99. PubMed ID: 19450112
[TBL] [Abstract][Full Text] [Related]
20. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
